CEP
ABBV icon

Chicago Equity Partners’s AbbVie ABBV Stock Holding History

Chicago Equity Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4.71M Sell
61,755
-7,545
-11% -$643K 0.47% 33
2019
Q4 		$6.14M Sell
69,300
-33,780
-33% -$2.8M 0.35% 52
2019
Q3 		$7.8M Sell
103,080
-14,750
-13% -$1.01M 0.37% 52
2019
Q2 		$8.57M Sell
117,830
-39,460
-25% -$3.1M 0.38% 50
2019
Q1 		$12.7M Sell
157,290
-21,335
-12% -$1.75M 0.49% 36
2018
Q4 		$16.5M Sell
178,625
-46,355
-21% -$4.08M 0.66% 21
2018
Q3 		$21.3M Sell
224,980
-3,085
-1% -$293K 0.63% 23
2018
Q2 		$21.1M Buy
228,065
+67,490
+42% +$6.59M 0.65% 21
2018
Q1 		$15.2M Buy
160,575
+124,875
+350% +$13.7M 0.49% 38
2017
Q4 		$3.45M Buy
35,700
+23,055
+182% +$2.17M 0.11% 258
2017
Q3 		$1.12M Sell
12,645
-5,530
-30% -$421K 0.04% 491
2017
Q2 		$1.32M Sell
18,175
-9,860
-35% -$663K 0.04% 452
2017
Q1 		$1.83M Buy
28,035
+13,180
+89% +$829K 0.05% 349
2016
Q4 		$930K Buy
14,855
+10,260
+223% +$626K 0.02% 471
2016
Q3 		$290K Sell
4,595
-2,435
-35% -$158K 0.01% 648
2016
Q2 		$435K Sell
7,030
-265,955
-97% -$16.2M 0.01% 517
2016
Q1 		$15.6M Buy
272,985
+192,325
+238% +$10.7M 0.46% 69
2015
Q4 		$4.78M Sell
80,660
-301,965
-79% -$17.4M 0.13% 159
2015
Q3 		$20.8M Buy
382,625
+31,730
+9% +$2.07M 0.58% 53
2015
Q2 		$23.6M Sell
350,895
-55,185
-14% -$3.6M 0.64% 51
2015
Q1 		$23.8M Buy
406,080
+127,450
+46% +$7.7M 0.63% 54
2014
Q4 		$18.2M Buy
278,630
+27,185
+11% +$1.71M 0.49% 68
2014
Q3 		$14.5M Sell
251,445
-26,790
-10% -$1.49M 0.38% 84
2014
Q2 		$15.7M Buy
278,235
+3,480
+1% +$183K 0.42% 79
2014
Q1 		$14.1M Sell
274,755
-21,570
-7% -$1.09M 0.39% 87
2013
Q4 		$15.6M Sell
296,325
-69,275
-19% -$3.4M 0.47% 79
2013
Q3 		$16.4M Sell
365,600
-287,190
-44% -$12.7M 0.51% 67
2013
Q2 		$27M Buy
+652,790
New +$28.6M 0.84% 33

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Chicago Equity Partners's ABBV Position: Q1 2020 in Review

Chicago Equity Partners reduced its AbbVie (ABBV) stake by 11% in Q1 2020, selling an estimated $643K and leaving 61,755 shares worth $4.71M. The position accounts for 0.47% of the portfolio, ranked #33.

Chicago Equity Partners first reported a position in ABBV in Q2 2013 and has held it in 28 quarters since. The position peaked at $27M in Q2 2013. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

  • Chicago Equity Partners held 61,755 shares of AbbVie worth $4.71M as of Q1 2020.
  • Chicago Equity Partners sold 7,545 AbbVie shares in Q1 2020, an estimated $643K.
  • AbbVie made up 0.47% of Chicago Equity Partners's portfolio in Q1 2020, its #33 holding.
  • Chicago Equity Partners first reported a position in AbbVie in Q2 2013 and has held it in 28 quarters since.
  • Chicago Equity Partners's AbbVie position peaked at $27M in Q2 2013.
  • 2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.